Clinical Trials Logo

Clinical Trial Summary

Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.


Clinical Trial Description

Rationale Infection with HIV causes significant morbidity and mortality, even among individuals who are virologically suppressed with combination anti-retroviral therapy (ART). ART is effective in prolonging life and enabling individuals who are HIV positive to live near-normal life spans. However, these individuals are increasingly developing a number of chronic diseases of aging, such as atherosclerotic cardiovascular disease (ASCVD). The proposed studies will examine the role of highly active antiretroviral therapy in restoring the mucosal immunity and the systemic effect on immune activation, bacterial translocation, and change in HIV-associated cardiovascular disease risk. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01869634
Study type Interventional
Source University of California, Davis
Contact
Status Completed
Phase Phase 4
Start date June 2013
Completion date December 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Completed NCT01490359 - Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men N/A
Completed NCT03143205 - Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men N/A
Completed NCT02738138 - A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Phase 3
Completed NCT01791465 - Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults Phase 4
Completed NCT01662336 - Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program N/A
Completed NCT01328158 - Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection N/A
Completed NCT01383005 - Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) N/A
Completed NCT00711009 - Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Phase 3
Completed NCT02817451 - DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Phase 3
Completed NCT02214173 - The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV N/A
Completed NCT03284645 - Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
Terminated NCT01737359 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. Phase 2
Active, not recruiting NCT05141422 - A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers Phase 1
Completed NCT01939197 - A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Phase 2/Phase 3
Completed NCT01447680 - Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing N/A
Not yet recruiting NCT05769413 - Awareness of Osteoporosis in HIV Patients
Withdrawn NCT01738555 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects Phase 2